As usual, Pfizer’s hot-shot breast cancer med Ibrance posted strong numbers in the fourth quarter, but that wasn't enough to bail Pfizer out on the earnings front.
If you’ve watched Pfizer’s recent dealmaking, you've noticed a trend: It likes buys that bring in new revenue, and quickly. That's a pattern the company intends to stick with.